SequelSEC

NANOVIRICIDES, INC. NNVC

Pharmaceutical Preparations · CIK 0001379006 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-06-30
Operating income
-$9.59M
Fiscal year ended 2025-06-30
Free cash flow
-$8.54M
Fiscal year ended 2025-06-30

NANOVIRICIDES, INC. (NNVC) reported revenue of $0 and net income of -$9.47M for the fiscal year ended 2025-06-30. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from NANOVIRICIDES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NANOVIRICIDES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-302024-06-302023-06-30
Revenue$0$0$0
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$9.59M-$8.52M-$8.94M
Net income-$9.47M-$8.29M-$8.59M
Research & development$5.55M$5.44M$6.39M
Weighted-average diluted sharesshares 15.12Mshares 11.87Mshares 11.63M
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPS$-0.63$-0.70$-0.74
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$4.04M$3.08M$2.55M
Selling & marketingUnavailableUnavailableUnavailable

Balance

NANOVIRICIDES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-302024-06-302023-06-30
Cash & equivalents$1.56M$4.80M$8.15M
Total assets$8.82M$12.82M$16.90M
Current assets$1.67M$4.97M$8.45M
Total liabilities$1.30M$1.36M$2.03M
Current liabilities$1.31M$1.36M$534.25K
Total equity incl. NCI$7.52M$11.46M$14.87M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailable

Cash flow

NANOVIRICIDES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-302024-06-302023-06-30
Operating cash flow-$8.48M-$6.32M-$5.67M
Capital expenditures$56.96K$156.56K$151.71K
Investing cash flow-$56.96K-$156.56K-$151.71K
Financing cash flow$5.30M$3.12M-$94.79K
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

NANOVIRICIDES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-302024-06-302023-06-30
Free cash flow-$8.54M-$6.47M-$5.82M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio1.28x3.66x15.81x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NNVC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-Q · Filed 2025-02-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.